ΒΙΒΛΙΟΓΡΑΦΙΑ
1. Golden
T., Stout A.P.: Smooth Muscle Tumors of the Gastrointestinal Tract and
Retroperitoneal Tissues. Surg Gynecol Obstet 1941;73:784-810
2. Stout
A.P.: Bizzare Smooth Muscle Tumors of the Stomach. Cancer 1962; 15: 400-409
3. Appelman
H.D.: Smooth Muscle Tumors of the Gastrointestinal Tract. What we know now that
Stout didn’t know. Am J Surg Pathol 1986; 10(suppl.1): 83-93
4. Mazur M.T., Clark H.B.: Gastric Stromal Tumors. Reappraisal of Histogenesis. Am J Surg Pathol 1983; 7:
507-519
5. Kindblom
L.G., Remotti H.E., Aldenborg F., Meis-Kindblom J.M.: Gastrointestinal
Pacemaker Cell Tumor (GIPACT): Gastrointestinal Stromal Tumors Show Phenotypic
Characteristics of the Interstitial Cells of Cajals. Am J Pathol
1998; 152:1259-1269
6. Nishida T.,
Hirota S.: Biological and Clinical Review of Stromal Tumors in the
Gastrointestinal Tract. Hist Histopathol 2000;15: 1293-1301
7. Miettinen
M., Lasota J.: Gastrointestinal Stromal Tumors – Definition, Clinical, Histological,
Immunohistochemical and Molecular Genetic Features and Differential Diagnosis. Virchows
Arch 2001; 438: 1-12
8. El-Rifay
W., Sarlomo-Ricala M., Miettinen M., et al.: DNA Copy Number Losses in
Chromosome 14: an early change in gastrointestinal stromal tumors. Cancer Res
1996; 56: 3230-3233
9. Bergman
F., Gunawan B., Hermanns B., et al.: Cytogenetic and Morphologic Characteristics
of Gastrointestinal Stromal Tumors. Recurrent Rearrangement of Chromosome 1 and
Losses of Chromosomes 14 and 22 as Common Anomalies. Verh Dtsch Ges Pathol
1998; 82: 275-278
10. O’Leary
T., Ernst S., Przygodzki R., et al.: Loss of Heterozygosity at 1p36 Predicts
Poor Prognosis in Gastrointestinal Stromal/Smooth Muscle Tumors. Lab Invest
1999; 79: 1461-1467
11. Fukasawa
T., Chong J.M., Sakurai S., et al.: Allelic Loss of 14q and 22q, NF2 Mutation,
and Genetic Instability Occur Independently of c-Kit Mutation of Gastrointestinal
Stromal Tumor. Jpn J Cancer Res 2000; 91: 1241-1249
12. Debiek-Rychter
M., Lasota J., Sarlomo-Rikala M., et al.: Chromosomal Aberrations in Malignant
Gastrointestinal Stromal Tumors: correlation with c-KIT gene mutation. Cancer
Genet Cytogenet 2001; 128: 24-30
13. Heinrich
M.C., Rubin B.P., Longley B.J., Flecher J.A.: Biology and Genetic Aspects of
Gastrointestinal Stromal Tumors: Kit activation and cytogenetic alterations. Hum
Pathol 2002; 33: 484-495
14. Heinrich
M.C., Corless C.L., Duensing A., et al.: PDGFRA Activating Mutations in
Gastrointestinal Stromal Tumors. Science 2003; 299: 708-710
15. Antonescu
C.R., Viale A., Sarran L., et al.: Gene Expression in Gastrointestinal Stromal
Tumors is Distinguished by KIT Genotype and Anatomic Site. Clin Cancer Res
2004; 10: 3282-3290
16. El-Rifay
W., Sarlomo-Ricala M., Anderson L.C., et al.: High-resolution Deletion Mapping
of Chromosome 14 in Stromal Tumors of the Gastrointestinal Tract Suggests Two
Distinct Tumor Suppressor Loci. Genes Chromosomes Cancer 2000; 27: 387-391
17. El-Rifay
W., Sarlomo-Ricala M., Anderson L.C., et al.: DNA Sequence Copy Number Changes
in Gastrointestinal Stromal Tumors: tumor progression and prognostic
signicance. Cancer Res 2000; 60: 3899-3903
18. Hirota
S., Isozaki K., Moriyama Y. et al: Gain of Function Mutations of c-KIT in Human
G.I. Stromal Tumors. Science 1998; 279: 577-580
19. Nakahara
M., Isozaki K., Hirota S. et al: A Novel Gain-of Function Mutation of c-KIT
Gene in Gastrointestinal Stromal Tumors. Gastroenterology 1998; 115:
1090-1095
20. Rubin
B.P., Singer S., Tsao L. et al: Kit Activation is a Ubiquitus Feature of
Gastrointestinal Stromal Tumors. Cancer Res 2001; 61: 8118-8121
21. Corless
C.L., McGreevy L., Haley A. et al.: KIT mutations are common in Incidental
Gastrointestinal Stromal Tumors One Centimeter or Less in Size. Am J Pathol
2002; 160: 1567-1572
22. Lux
M.L., Rubin B.P., Biase T.L. et al: KIT Extracellular and Kinase Domain Mutations
in G.I. Stromal Tumors. Am J Pathol 2000; 156: 791-795
23. Heinrich
M.C., Corless C.L., Demetri G.D., et al.: Kinase Mutations and Imatinib Response
in Patients with Metastatic Gastrointestinal Stromal Tumor. J Clin Oncol 2003;
21: 4342-4349
24. Corless
C.L., Fletcher J.A., Heinrich M.C. Biology of Gastrointestinal Stromal Tumors J
Clin Oncol 2004; 22: 3813-3825
25. Lasota
J., Wozniak A., Sarlomo-Ricala M., et al.: Mutations in Exon 9 and 13 of KIT
Gene Are Rare Events in Gastrointestinal Stromal Tumors. A study of 200 cases.
Am J Pathol 2000; 157: 1091-1095
26. Hirota
S., Nishida T., Isozaki K., et al.: Gain- of- Function Mutation at the Extracellular
Domain of KIT in Gastrointestinal Stromal Tumors. J Pathol 2001; 193: 505-510
27. Antonescu
C.R., Sommer G., Sarran L., et al.: Association of KIT Exon 9 Mutations with
Nongastric Primary Site and Aggressive Behavior: KIT mutation analysis and
clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res
2003; 9: 3329-3337
28. Kinoshita
K., Isozaki K., Hirota S., et al.: C-Kit Gene Mutation at Exon 17 or 13 is Very
Rare in Sporadic Gastrointestinal Stromal Tumors. J Gastroenterol Hepatol 2003;
18: 147-151
29. Hirota
S., Ohashi A., Nishida T., et al: Gain-of-Function Mutations of
Platelet-Derived Growth Factor Receptor Alpha in Gastrointestinal Stromal
Tumors. Gastroenterology 2003;
125: 660-667
30. Corless
C.L., Schroeder A., Griffith D, et al.: PDGFRA Mutations in Gastrointestinal
Stromal Tumors: frequency, spectrum and in vitro sensitivity to imatinib. J
Clin Oncol 2005; 23: 5357-5364
31. Agaimy
A., Terracciano L.M., Dirnhofer S., et al.: V600E BRAF Mutations Are Alternative
Early Molecular Events in a Subset of
KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors. J Clin Pathol 2009; 62:
613-616
32. Rubin
P.B. Gastrointestinal Stromal Tumours: an update. Histopathology 2006; 48:
83-96
33. Grady
W.M.: GISTs: The Revolution Continues (Editorials). Gastroenterology 2003; 125: 967-978
34. Berman
J., and O’Leary T.J.: Gastrointestinal Stromal Tumors Workshop. Hum Pathol
2001; 32: 578-582
35. De
Matteo R.P., Heinrich M.C., El-Rifal W.M., Demetri G.: Clinical Management of
Gastrointestinal Stromal Tumors: Before and After STI-571. Hum Pathol
2002; 33: 466-477
36. Fletcher
C.D.M., Berman J.J., Corless C. et al: Diagnosis of Gastrointestinal Stromal
Tumors: A Consensus Approach. Hum Pathol 2002; 33: 459-465
37. Goettsch
W.G., Bos S.D., Breekveldt-Postma N., et al.: Incidence of Gastrointestinal
Stromal Tumours is Underestimated: results of a nation-wide study. Eur J Cancer
2005; 41: 2868-2872
38. Nilsson
B., Bümming P., Meis-Kindblom J.M., et al.: Gastrointestinal Stromal Tumors:
the incidence, prevalence, clinical course, and prognostication in the preimanitib
mesylate era—a population-based study in western Sweden. Cancer 2005; 15:
821-829
39. Emory
T.S., Sobin L.H., Lukes L. et al: Prognosis of Gastrointestinal Smooth Muscle (Stromal)
Tumors: Dependence on Anatomic Site. Am J Surg Pathol 1999;23: 82-87
40. Goldblum
J.R., Appelman H.D.: Stromal Tumors of the Deuodenum: A Histologic and
Immunohistochemical Study of 20 Cases. Am J Surg Pathol 1995; 19: 71-80
41. Tworek
J.A., Appelman H.D., Singleton T.P. et al: Stromal Tumors of the Jejunum and
Ileum. Mod Pathol 1997; 10: 200-209
42. Tworek
J.A., Goldblum J.R., Weiss S.W. et al: Stromal Tumors of the Abdominal Colon: A
Clinicopathologic Study of 20 Cases. Am J Surg Pathol 1999; 23: 937-945
43. Tworek
J.A., Goldblum J.R., Weiss S.W. et al: Stromal Tumors of the Anorectum: A
Clinicopathologic Study of 22 Cases. Am J Surg Pathol 1999; 23: 946-954
44. Miettinen
M., Sarlomo-Rikala M., Sobin L.H. et al: Esophageal Stromal Tumors: A
Clinicopathologic, Immunohistochemical and Molecular Genetic Study of 17 Cases
and Comparison with Esophageal Leiomyomas and Leiomyosarcomas. Am J Surg
Pathol 2000; 24: 211-222
45. Miettinen
M., Monihan J.M., Sarlomo-Rikala M. et al: Gastrointestinal Stromal
Tumors/Smooth Muscle Tumors (GISTs) Primary in the Omentum and Mesentery:
Clinicopathologic and Immunohistochemical Study of 26 Cases. Am J Surg
Pathol 1999; 23: 1109-1118
46. Reith
J.D., Goldblum J.R., Lytes R.H.: Extragastrointestinal (soft tissue) Stromal
Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of Outcome.
Mod Pathol 2000; 13: 577-585
47. Weiss
S.W., Goldblum J.R.: Extragastrointestinal Stromal Tumors. In Weiss S.W.,
Goldblum J.R. (eds): Enzinger and Weiss soft tissue tumors, 4th ed.
St Louis,MO,Mosby, 2001,pp 749-768
48. Ortiz-Hidalgo
C., de Leon Bojorge B., Albores-Saavedra J.: Stromal Tumors of the Gallbladder
with Phenotype of Interstitial Cells of Cajals. A Previously Unrecognized
Neoplasm. Am J Surg Pathol 2000; 24: 1420-1423
49. Lasota
J., Carlson J.A., Miettinen M.: Spindle Cell Tumor of the Urinary Bladder Serosa
with Phenotypic and Genotypic Features of G.I.Stromal Tumors. Arch Pathol
Lab Med 2000; 124: 894-897
50. Miettinen
M., Sobin L.H.: Gastrointestinal Stromal Tumors in the Appendix: a clinicopathologic
and immunohistochemical study of four cases. Am J Surg Pathol 2001; 25:
1433-1437
51. Daum
O., Klecka J., Ferda J., et al.: Gastrointestinal Stromal Tumor of the Pancreas:
case report with documentation of KIT gene mutation. Virchows Arch. 2005; 446:
470-472
52. Thomas R.M., Sobin L.H.: Gastrointestinal
Cancer Incidence and Prognosis by Histologic Type, SEER population-based data
1973-1987.Cancer 1987; 75: 154-170
53. De
Matteo R.P., Lewis J.J., Leung D., et al.: Two Hundred Gastrointestinal Stromal
Tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;
231: 51-58
54. Durham
M.M.,Gow K.W., Shehata B.M. et al: Gastrointestinal Stromal Tumors Arising from
Stomach: A report of three children. J Pediatr Surg 2004; 39: 1495-1499
55. Cheung
M.C., Zhuge Y., Yang R., Koniaris L.G.: Disappearance of Racial Disparities in
Gastrointestinal Stromal Tumor Outcomes. J Am Coll Surg 2009; 209: 7-16
56. Gasparotto
D., Rossi S., Bearzi I et al.: Multiple Primary Sporadic Gastrointestinal
Stromal Tumors in the Adult: An underestimated entity. Clin Cancer Res 2008;
14: 5715-5721
57. Arnogiannaki
N., Martzoukou I., Kountourakis P. et al.: Synchronous Presentation of GISTs
and Other Primary Neoplasms: A Single Center Experience. In vivo 2010, 24:
109-116
58. Nishida
T., Hirota S., Tanigushi M et al: Familial Gastrointestinal Stromal Tumors with
Germline Mutation of the Kit Gene. Nat Genet 1998; 19: 323-324
59. Hirota
S., Nishida T., Isozaki K. et al: Familial Gastrointestinal Stromal Tumors
Associated with Dysphagia and Novel Type Germline Mutation Of KIT Gene.
Gastroenterology 2002; 122:
1493-1499
60. Maeyama
H., Hidaka E., Ota H. et al: Familial Gastrointestinal Stromal Tumors wit
Hyperpigmentation: Association with a germline mutation of the c-kit.
Gastroenterology 2001; 120: 210-215
61. O’Brien
P., Kapusta L., Dardick I. et al: Multiple Familial Gastrointestinal Autonomic
Nerve Tumors and Small Intestinal Neuronal Dysphagia. Am J Surg Pathol 1999;
23: 198-204
62. Hirota
S., Okazaki T., Kitamura Y. et al: Multiple Familial Gastrointestinal Autonomic
Nerve Tumors with Hyperplasia of Intestinal Cells of Cajals is Germline Mutation
of the c-Kit Gene. Am J Surg Pathol 2000; 24: 326-327
63. Isozaki
K., Terris B., Belghiti J., et al: Germline Activating Mutation in the Kinase
Domain of Kit Gene in Familial Gastrointestinal Stromal Tumors. Am J Surg
Pathol 2000; 157: 1581-1585
64. Li
F.P., Flecher J.A., Heinrich M.C. et al: Familial Gastrointestinal Stromal
Tumor Syndrome: Phenotypic and Molecular Features in a Kindred. J Clin Oncol
2005; 23: 2735-2743
65. Chompret
A., Kannengiesser C., Barrois M. et al: PDGFRA Germline Mutation in a Family
with Multiple Cases of Gastrointestinal Stromal Tumors. Gastroenterology 2004;
126: 318-321
66. Beghini
A., Tibiletti M.G., Roversi G. et al.: Germline Mutation in the Juxtamembrane
Domain of the Kit Gene in a Family with Gastrointestinal Stromal Tumors and
Urticaria Pigmentosa. Cancer 2001; 92: 657-662
67. Zoller
M.E., Rembeck B., Oden A. at al: Malignant and Benign Tumors in Patients with
Neurofibromatosis Type I in a Defined Swedish Population. Cancer 1997; 79:
2125-2131
68. Min
K.W., Balaton A.J.: Small Intestinal Stromal Tumors with Skeinoid Fibers in
Neurofibromatosis: Report of four cases
with ultrastructural study of skeinoid fibers from paraffin blocks. Ultrastruct
Pathol 1993; 17: 307-314
69. Takasawa
Y., Sakurai S., Sakuma Y., et al: Gastrointestinal Stromal Tumors of Neurofibromatosis
Type I (Von Recklinhausen’s disease). Am J Surg Pathol 2005; 29: 755-763
70. Yantiss
R.K., Rosenberg A.E., Sarran I. et al: Multiple Gastrointestinal Stromal Tumors
in Type I Neurofibromatosis: a pathognomonic and molecular study. Mod Pathol
2005; 18: 475-484
71. Carney
J.A., Sheps S.G., Go V.L.W., Gordon H.: Triad of Gastric Leiomyosarcoma,
Functioning Extra-adrenal Paragagglioma and Pulmpnary Chondroma. N Engl J Med
1977; 296: 1517-1518
72. Carney
J.A.: The Triad of Gastric Epithelioid Leiomyosarcoma, Functioning
Extra-adrenal Paraganglioma and Pulmonary Chondroma. Cancer 1979; 43: 374-382
73. Carney
J.A.: Gastric Stromal Sarcoma, Pulmpnary Chondroma and Extra-adrenal Paragagglioma
(Carney Triad): Natural history, adreno-cortical component, and possible
familial occurrence. Mayo Clin Proc 1999; 74: 543-552
74. Price
V.E., Zielenska M., Chilton-MacNeil S. et al: Clinical and Molecular Characteristics
of Pediatric Gastrointestinal Stromal Tumors (GISTs). Pediatr Blood Cancer
2005; 45: 20-24
75. Prakash
S., Sarran L., Socci N. et al: Gastrointestinal Stromal Tumors in Children and
Young Adults: a clinicopathologic, molecular and genomic study of 15 cases and
review of the literature. J Pediatr Hematol Oncol 2005; 25: 179-189
76. Diment
J., Tamborini E., Casali P. et al: Carney Triad: case report and molecular
analysis of gastric tumor. Hum Pathol 2005; 36: 112-116
77. Carney
J.A., Stratakis C.A.: Familial Paragagglioma and gastric Stromal Sarcoma: A new
syndrome distinct from the Carney triad. Am J Med Genet 2002; 108: 132-139
78. Stratakis
C.A., Carney J.A.: The Triad of Paragagglioma, Gastric Stromal Tumors and
Pulmonary Chondromas (Carney-Stratakis Sydrome): Molecular genetics and
clinical implications. J Int Med 2009; 266: 43-52
79. Alrashdi
I., Bano G., Maher E.R., Hodgson S.V. Carney Triad Versus Carney-Stratakis
Syndrome: Two cases which illustrate the difficulty in distinguishing between
these two conditions in individual patients. Fam Cancer 2010; 9: 443-447
80. Lau
S., Tam K.F., Kam C.K. et al.: Imaging of Gastrointestinal Stromal Tumors
(GIST). Clin Radiol 2004; 59: 487-498
81. Nguyen
V.H., Taylor A.: Gastrointestinal Stromal Tumors Leiomyoma /Leiomyo-sarcoma.
2008; Emedicine.medscape.com/article/369803
82. Pidhorecky I., Cheney R.T., Kraybill W.G., Gibbs J.F.:
Gastrointestinal Stromal Tumors: current diagnosis, biologic behavior, and
management. Ann Surg Oncol 2000; 7: 705-712
83. Poylin V.Y.,
Fisher J.E. Small Bowel Tumors: In Cameron J.L.. Current Surgical Therapy. 9th
ed., Philadelphia, Mosby Inc., 2008, sect3, ch.32
84. Ghanem
N., Altehoefer C., Furtwangler A. et al.: Computed Tomography in Gastrointestinal
Stromal Tumors. Eur Radiol 2003; 13: 1669-1678
85. Tateishi
U., Hasegawa T., Satake M., Moriyana N.: Gastrointestinal Stromal Tumors.
Correlation of Computed Tomography Findings with Tumor Grade and Mortality. J
Comput Assist Tomogr 2003; 27: 792-798
86. Miller F.H., Hwang C.M. An Initial Experience Using
Helical CT Imaging to Detect Obscure Gastrointestinal Bleeding. J Clin
Imaging 2004; 28: 245-251
87. Maglinte D.D., Siegelman E.S., Kelvin F.M.:
MR-Enteroclysis: The future of small-bowel imaging. Radiology
2000; 215: 639-641
88. Moawad F.J., LaRock T.R., Biondi M.C. et al.: A case
of Obscure Gastrointestinal Bleeding Secondary to a Small Bowel
Gastrointestinal Stromal Tumor Detected by Magnetic Resonance Enterography. Medscape J
Med 2008; 10: 263
89. Tada
M., Misaki F., Keiichi K.: Pediatric Enteroscopy with a Sonde-type Small Intestinal
Fiberscope (SSIF-type VI). Gastrointest Endosc 1983; 29: 44-47
90. Shidu
R., Sanders D.S., McAlindon M.E., Thomson M.: Capsule Endoscopy and Enteroscopy:
modern modalities to investigate the small bowel in paediatrics. Arch Dis Child
2008; 93: 154-159
91. Foutch
P.G., Sawyer R., Sanowski R.A.: Push-enteroscopy for Diagnosis of Patients with
Gastrointestinal Bleeding of Obscure Origin. Gastrointest Endosc 1990; 36:
337-341
92. Nguyen
N.Q., Rayner C.K., Shoeman M.N.: Push Enteroscopy Alters Management in a
Majority of Patients with Obscure Gastrointestinal Bleeding. J Gastrointest
Hepatol 2005; 20: 716-721.
93. Iddam
G., Meron G., Glukhovski A., Swain P.: Wireless Capsule Endoscopy. Nature 2000;
405: 417
94. Yamamoto
H., Sekine Y., Sato Y., et al.: Total Enteroscopy with a Non-surgical Steerable
Double-balloon Method. Gastrointest Endosc 2001; 53: 216-220
95. Jonnalagada S., Prakash C.: Intestinal Strictures Can
Impede Wireless Capsule Enteroscopy. Gastrointest Endosc 2003; 57:
418-420
96. Barkin J., Friedman S.: Wireless Capsule Endoscopy
Requiring Surgical Intervention: The world’s experience (abstract). Am J
Gastrointerol 2002; 97: A907. Cited in Shidu R., Sanders D.S., McAlindon M.E.,
Thomson M.(65)
97. Rastogi A., Schoen R.E., Slivka A.: Diagnostic Yield
and Clinical Outcomes of Capsule Endoscopy. Gastrointest Endosc 2004; 60: 959-964
98. Costamagna G., Shah S.K., Riccioni M.E. et al.: A
Prospective Trial Comparing Small Bowel Radiographs and Video Capsule Endoscopy
for Suspected Small Bowel Disease. Gastroenterology 2002; 123:
999-1005
99. Lewis B., Swain P.: Capsule Endoscopy in the Evaluation
of Patient Suspected Small Intestinal Bleeding. Gastrointest Endosc 2002;
56: 349-353
100. Scapa E.,
Jacobs H., Lewkowicz S. Et al.: Initial Experience of Wireless Capsule
Endoscopy for Evaluating Occult Gastrointestinal Bleeding and Suspected Small
Bowel Pathology. Am J Gastroenterol 2002; 97: 2276-2279
101. Mylonaki
M., Fritscher-Ravens A., Swain P.: Wireless Capsule Endoscopy: A comparison
with push-enteroscopy in a patient with gastroscopy and colonoscopy negative
gastrointestinal bleeding. Gut 2003; 52: 1122-1126
102. Adler D.G.,
Knipschield M., Gostout C.: A Prospective Comparison of Capsule Endoscopy and
Push-Enteroscopy in Patients with GI Bleeding of Obscure Origin. Gastrointest
Endosc 2004; 59: 492-498
103. Kraus K.,
Hollerbach S., Pox C.: Diagnostic Utility of Capsule Endoscopy in Occult
Gastrointestinal Bleeding. Dtsch med Wochenschr 2004; 129: 1369-1374
104. Shidu R.,
Sanders D.S., McAlindon M.E. Gastrointestinal Capsule Endoscopy: from tertiary
centers to primary care. BMJ 2006; 332: 528-531
105. Cobrin
G.M., Pittman R.H., Lewis B.L.: Increased Diagnostic Yield of Small Bowel
Tumors with Capsule Endoscopy. Cancer 2006; 107: 22-27
106. Estevez E.,
Gonzalez-Conde B., Vazquez-Iglesias J.L. et al.: Incidence of Tumoral Pathology
According to Study Using Capsule Endoscopy for Patients with Obscure
Gastrointestinal Bleeding. Surg Endosc 2007; 21: 1776-1780
107. Yamamoto H., Kita H., Sunada K., et
al.: Clinical Outcomes of Double-balloon Endoscopy for the diagnosis and
Treatment of Small-intestinal Diseases. Clin Gastroenterol Hepatol 2004; 2:
1010-1016
108. Di Caro S., May A., Heine D.G.N., et
al.: The European Experience with Double-balloon Enteroscopy: indications,
methodology, safety and clinical impact. Gastrointest Endosc 2005; 62: 545-550
109. May A.,
Nachbar L., Ell C.: Double-Balloon Enteroscopy (push and pull enteroscopy) of
the Small Bowel: feasibility and diagnostic and therapeutic yield in patients
with suspected small bowel disease. Gastrointest Endosc 2005; 62: 62-70
110. May A., Nachbar L., Schneider M., Ell
C.: Prospective Comparison of Push Enteroscopy and Push-and-pull Enteroscopy in
Patients with Suspected Small-bowel Bleeding. Am J Gastroenterol 2006; 101:
2016-2024
111. Heine G.D.N., Hadithi M., Groenen
M.J.M., et al.: Double-balloon Enteroscopy: indications, diagnostic yield, and
complications in a series of 275 patients with suspected small bowel disease.
Endoscopy 2006; 38: 42-48
112. Mehdizadeh S., Ross A., Gerson L., et
al.: What is the Learning Curve Associated with Double-balloon Endoscopy?
Technical details and early experience in 6 U.S. tertiary care centers.
Gastrointest Endosc 2006; 64: 740-750
113. Sun B.,
Rajan E., Cheng S. et al.: Diagnostic Yield and therapeutic Impact of
Double-Balloon Enteroscopy in a Large Cohort of Patients with Obscure
Gastrointestinal Bleeding. Am J Gastroenterol 2006; 101: 2011-2015
114. Gross S.A., Stark M.A.: Initial
Experience with Double-balloon Enteroscopy at a U.S. Center. Gastrointest
Endosc 2008; 67: 890-897
115. Tsujikawa
T., Saitoh Y., Andoh A. et al.: Novel Single-Balloon Enteroscopy for Diagnosis
and Treatment of the Small Intestine: Preliminary experiences. Endoscopy
2008; 40: 11-15
116. Akerman
P.A., Cantero D., Avila J et al.: The Spiral EndoscopyExperience in 101
Consecutive Patients: safety and efficacy using the discovery SB. Gastrointest
Endosc 2008; 67: AB92-AB93
117. Tio T.L., Tytgat G.N.J., den Hartog
Jager F.C.A. : Endoscopic Ultrasonography for the Evaluation of Smooth Muscle
Tumors in the Upper Gastrointestinal Tract: an experience with 42 cases.
Gastrointest Endosc 1990; 36: 342-350
118. Chak A., Canto M.I., Rosch T. et al.:
Endosonographic Differentiation of Benign and Malignant Stromal Cell Tumors.
Gastrointest Endosc 1997; 45: 468-473
119. Palazzo L., Landi B., Cellier C., et
al.: Endosonographic Features Predictive of Benign and Malignant
Gastrointestinal Stromal Cell Tumors.
Gut 2000; 46: 88-92
120. Kim G. H., Park D.Y., Kim S. et al.:
Is it Possible to Differentiate Gastric GISTs from Gastric Leiomyomas by EUS?
World J Gastroenterol 2009; 15: 3376-3381
121. Rösch T., Kapfer B., Will U. et al.:
Accuracy of Endoscopic Ultrasonography in Upper Gastrointestinal Submucosal
Lesions: a prospective multicenter study. Scand J Gastroenterol 2002;37:
856-862
122. Belloni M., De Fiori E., Mazzarol G.
et al.: Endoscopic Ultrasound and Computed Tomography in Gastric Stromal
Tumors. Radiol Med 2002; 103: 65-73
123. Ha C.H.,
Shach R., Chen J.,
et al.:
Diagnosis and Management of GI Stromal Tumors by EUS-FNA: a survey of opinions
and practices of endosographers. Gastrointest Endosc 2009; 69: 1039-1044
124. Hunt G.C.,
Smith P.P.,
Faigel D.O.:
Yield of Tissue Sampling for Submucosal Lesions Evaluated by EUS. Gastrointest
Endosc 2003; 57: 68-72
125. Philiper M.,
Hollerbach S., Gabbert H.E. et al.:
Prospective Comparison of Endoscopic Ultrasound-guided Fine-needle Aspiration
and Surgical Histology in Upper Gastrointestinal Submucosal Tumors. Endoscopy
2010; 42: 300-305
126. Hollerbach
P.M., Gabbert H.E., Heikaus S., et al.: Prospective Comparison of Endoscopic
Ultrasound-Guided Fine-Needle Aspiration and Surgical Histology in Upper
Gastrointestinal Submucosal Tumors. Endoscopy 2010; 42: 300-305
127. Hwang J.H.,
Rulyak S.D.,
Kimmey M.B.:
American Gastroenterological Association Institute Technical Review on the
Management of Gastric Subepithelial Masses. Gastroenterology 2006; 130:
2217-2228
128. Akahoshi K., Sumida Y.,
Matsui N., et al.:
Preoperative Diagnosis of Gastrointestinal Stromal Tumors by Endoscopic
Ultrasound-guided Fine-needle Aspiration. W J Gastroenterol 2007; 13: 2077-2082
129. Akahoshi K.,
Oya M.:
Gastrointestinal Stromal Tumor of the Stomach: How to manage. W J Gastroenterol 2010; 2: 271-277
130. Gerke H.,
Rizk M.K.,
Vanderheyden A.D.,
Jensen C.S.:
Randomized Study Comparing Endoscopic Ultrasound-guided Trucut Biopsy and Fine
Needle Aspiration with High Suction. Cytopathology 2010; 21: 44-51
131. Al–Haddat M.,
DeWitt J.:
Editorial: EUS-guided Sampling of Suspected GI Mesenchymal Tumors: cells, cores
or a combination? Gastrointest Endosc 2009; 69: 1224-1227
132. Ando N.,
Goto H., Niwa Y.,
et al.:
The Diagnosis of GI Stromal Tumors with EUS-guided Fine-needle Aspiration with
Immunohistochemical Analysis. Gastrointest Endosc 2002; 55: 37-43
133. Aithal G.P.,
Anagnostopoulos G.K.,
Tam W., et al.:
EUS-guided Tissue-sampling: Comparison of ‘’dual sampling’’ (Trucut biopsy plus
FNA) with ‘’Sequential sampling’’ (Trucut biopsy and then FNA as required).
Endoscopy 2007; 30: 725-730
134. Jenssen C.,
Diedrich C.F.:
Endoscopic Ultrasound-guided Fine-needle Aspiration Biopsy in Gastroenterology-
An Overview. Best Practice Res Clin Gastroenterol 2009; 23: 743-759
135. Gomes A.L.,
Bardales R.H.,
Milanezi F., et al.:
Molecular Analysis of c-Kit and PDGFRA in GISTs Diagnosed by EUS. Am J Clin
Pathol 2007; 127: 89-96
136. Alavi A., Dann R.W., Baum S., et al.:
Scintigraphic Detection of Acute Gastrointestinal Bleeding. Radiology 1977;
124: 753-756
137. Baum S., Athanasoulis C.A., Waltman
A.C., et al.: Gastrointestinal Hemorrhage. II. Angiographic Diagnosis and
Control. Adv Surg 1973; 7: 149-198
138. Rollins E.S., Picus D., Hicks M.E.,
et al.: Angiography is Useful in Detecting the Source of Chronic
Gastrointestinal Bleeding of Obscure Origin. Am J Roentgenol 1991; 156: 385-388
139. Sheedy F.P. II., Fulton R.E., Atwell
D.T.: Angiographic Evaluation of Patients with Chronic Gastrointestinal
Bleeding. Am J Roentgenol Radium Ther Nucl Med 1975; 123: 338-347
140. Bloomfeld R.S., Smith T.P., Schneider
A.M., et al.: Provocative Angiography in Patient with Gastrointestinal Bleeding
of Obscure Origin. Am J Gastroenterol 2000; 95: 2807-2812
141. Shetzline M.A., Suhocki P., Dash R.,
Rockey D.C.: Provocative Angiography in Obscure Gastrointestinal Bleeding.
South Med J 2000; 93: 1205-1208
142. Delgado
Bolton R.C., Izarduy L.P., Carreras Delgado J.L.: Positron Emission Tomography
and Positron Tomography/Computed Tomography in the Evaluation of Response to
Chemotherapy. Cancer Chemother Rev 2008; 3: 77-86
143. Demetri G,D., Benjamin R., Blanke
C.D. et al.: NCCN Task Force Report: Optimal management of patients with
gastrointestinal stromal tumor (GIST)-expansion and update of NCCN clinical
practice guidelines. JNCCN 2004; 2(suppl 1): S1-S26
144. Hasegawa T., Matsuno Y., Shimoda et
al.: Gastrointestinal Stromal Tumors: Consistent CD117 immunostaining for
diagnosis, and prognostic classification based on tumor size and MIB-1 grade.
Hum Pathol 2002; 33: 669-676
145. De Silva
C.M., Reid R.: Gastrointestinal Stromal Tumors (GIST): C-Kit mutations, CD117
expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol
Oncol Res 2003; 9: 13-19.
146. Μiettinen
M., Sobin L.H., Lasota J. Gastrointestinal Stromal Tumors of the Stomach: a
clinicopathologic, immunohistochemical, and molecular genetic study of 1765
cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68
147. Wasag B.,
Debiec-Rychter M., Pauwels P. Et al.: Differential Expression of KIT/PDGFRA
Mutant Isoforms in Epithelioid and Mixed Variants of Gastrointestinal Stromal Tumors
Depends Predominantly on the Tumor Site. Mod Pathol 2004; 17: 889-894
148. Wieczorek
T.J., Faquin W.C., Rubin B.P. et al.: Cytologic Diagnosis of Gastrointestinal
Stromal Tumor with Emphasis on the Differential Diagnosis with Leiomyosarcoma. Cancer
2001; 93: 276-287
149. Suster S.,
Fletcher C.D.: Gastrointestinal Stromal Tumors with Prominent Signet-ring Cell
Features. Mod Pathol 1996; 9: 609-613
150. Shek T.W.,
Luk I. S., Loong F. Et al.: Inflammatory Cell-rich Gastrointestinal Autonomic
Nerve Tumor. An expansion of its histologic spectrum. Am J Surg Pathol 1996;
20: 325-331
151. Min K.W.:
Small Intestinal Stromal Tumors with Skeinoid Fibers. Clinicopathological,
immunohistochemical, and ultrastructural investigations. Am J Surg
Pathol 1992; 16: 145-155
152. Yantiss
R.K., Rosenberg A.E., Selig M.K., et al.: Gastrointestinal Stromal Tumors: an
ultrastructural study. Int J Surg Pathol 2002; 10: 101-113
153. Lee J.R.,
Joshi V., Griffin J.W.,Jr, et al.: Gastrointestinal Autonomic Nerve Tumor:
immunohistochemical and molecular identity with gastrointestinal stromal tumor.
Am J Surg Pathol 2001; 25: 979-987
154. Miettinen
M., Virolainen M, Sarlomo-Ricala M.: Gastrointestinal Stromal Tumors-value of
CD34 antigen in their identification and separation from true leiomyomas and
schwannomas. Am J Surg Pathol 1995; 19: 207-216
155. Sarlomo-Rikala
M., Kovatich A.J., Barucevicius A. Et al.: CD117: a sensitive marker for
gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol
1998; 11: 728-734
156. Medeiros F., Corless C.L., Duencing A. et al.:
KIT-negative Gastrointestinal Stromal Tumors: proof of concept and therapeutic
implications. Am J Surg Pathol 2004; 28: 889-894
157. Debiec-Rychter
M., Wasag B., Stul M et al.: Gastrointestinal Stromal Tumors (GISTs) negative
for KIT (CD117 antigen) Immunoreactivity. J Pathol 2004; 202: 430-438
158. Miettinen
M., Sobin L.H., Sarlomo-Rikala M.: Immunohistochemical Spectrum of GISTs at
Different Sites and their Differential Diagnosis with Reference to CD117(KIT). Mod Pathol
2000; 13: 1134-1142
159. Miettinem M., Sarlomo-Ricala M., Lasota J.:
KIT expression in Angiosarcomas and Fetal Endothelial Cells: lack of mutations
of exon 11 and exon 17 of C-kit. Mod Pathol 2000; 13: 536-541
160. West R.B.,
Corless C.L., Chen X., et al.: The Novel Marker, DOG1, is Expressed Ubiquitously
in Gastrointestinal Stromal Tumors Irrispective of KIT or PDGFRA Mutation
Status. Am J Pathol 2004; 165: 107-113
161. Espinoza
I., Lee C.H., Kim M.K., et al.: A Novel Monoclonal Antibody Against Dog I is a
Sensitive and Specific Marker for Gastrointestinal Stromal Tumors. Am J Surg
Pathol 2008; 32: 210-218
162. Liegl B.,
Hornick J.L., Corless C.L., Fletcher C.D.: Monoclonal Antibody DOG 1.1 Shows
High Sensitivity than KIT in the Diagnosis of Gastrointestinal Stromal Tumors,
Including Unusual Subtypes. Am J Surg Pathpl 2009; 33: 437-446
163. Blay P., Astudillo A., Buesa J.M., et al.:
Protein Kinase C Theta is Highly Expressed in Gastrointestinal Stromal Tumors
but not in Other Mesenchymal Neoplasias. Clin Cancer Res 2004; 10: 4089-4095
164. Bragio
D.A., Romano S., Small I.A., et al.: Protein Kinase C θ (PKCθ)
Expression as a Potential Diagnostic Marker for KIT-negative GIST. J Clin
Oncol 2009; 27:15s(abstr 10561)
165. Miettinen
M., Sarlomo-Ricala M., Sobin L.H, Lasota J.: Gastrointestinal Stromal Tumors
and Leiomyosarcomas in the Colon: a clinicopathologic, immunohistochemical,
molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24:
1339-1352
166. Sarlomo-Rikala
M, Miettinen M.: Gastric Schwannoma-a clinicopathological analysis of six
cases. Histopathology 1995; 27: 355-360
167. Miettinen
M., Shekitka K.M., Sobin L.H.: Schwannomas in the Colon and Rectum: a
clinicopathologic and immunohistchemical study of 20 cases. Am J Surg
pathol 2001; 25: 846-855
168. Hasegawa
T., Yang P., Kagawa N., et al.: CD34 Expression by Inflammatory Fibroid Polyps
of the Stomach. Mod Pathol 1997; 10: 451-456
169. Lasota J.,
Wang Z-F., Sobin L.H., Miettinen M.: Gain-Of-Function PDGFRA Mutations, Earlier
Reported in Gastrointestinal Stromal Tumors, Are Common in Small Intestinal
Inflammatory Fibroid Polyps. A study of 60 bcases. Mod Pathol 2009; 22: 1049-1056
170. Pantanowitz
L., Antonioli D.A., Pinkuw G.S. et al.: Inflammatory Fibroid Polyps of the
Gastrointestinal Tract: evidence for a dendritic cell origin. Am J Surg
Pathol 2004; 28: 107-114
171. Yantiss
R.K., Spiro I.J., Compton C.C., Rosenberg A.E.: Gastrointestinal Stromal Tumors
Versus Intra-abdominal Fibromatosis of the Bowel Wall. Am J Surg
Pathol 2000; 24: 947-957
172. Hornick
J.L., Fletcher C.D.: Immunohistochemical Staining for KIT(CD117) in Soft Tissue Sarcomas is
Very Limited in Distribution. Am J Clin Pathol 2002; 117: 188-193
173. Miettinen
M.: Are Desmoid Tumors Kit Positive [letter]? Am J Surg Pathol 2001; 25:
549-550
174. Lukas D.R.,
Al-Abbadi M., Tabaczka P., et al.: C-Kit Expression in Desmoid Fibromitosis:
Comparative Immunohistochemical Evaluation of Two Commersial Antibodies. Am J Clin
Pathol 2003;119: 339-345
175. Montgomery
E., Torbenson M.S., Kaushal M., et al.: Beta-Catenin Immunohistochemistry
Separates Mesenteric Fibromatosis from Gastrointestinal Stromal Tumors and
sclerosing Mesenteritiw. Am J Surg Pathol 2002; 26: 1296-1301
176. Carlson
J.W., Fletcher C.D.: Immunohistochemistry for Beta-Catenin in the Differential
Diagnosis of Spindle Cell Lesions: analysis of a series and review of the
literature. Histopathology 2007; 51: 509-514
177. Miettinen
M., Kopczynski J., Makhlouf H.R., et al.: Gastrointestinal Stromal Tumors,
Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A
Clinicopathologic, Immunohistochemical , and Molecular Genetic Study of 167
Cases. Am J Surg Pathol 2003; 27: 625-641
178. Appelman
H., Helwig E.B.: Cellular Leiomyomas of the Stomach in 49 Patients. Arch Pathol
Lab Med 1977;101: 373-377
179. Ueyama T.,
Guo K.J., Hashimoto H., et al.: A Clinicopathologic and Immunohistochemical
Study of Gastrointestinal Stromal Tumors. Cancer 1992; 69: 947-955
180. Brainard
J.A., Goldblum J.R.: Stromal Tumors of the Jejunum and Ileum: A
clinicopathologic study of 39 cases. Am J Surg Pathol 1997; 21: 407-416
181. Miettinen
M., Furlong M., Sarlomo-Rikala M., et al.: Gastrointestinal Stromal Tumors,
Intramural Leiomyomas, and Leiomyosarcomas in the Rectum and the Anus: A
clinicopathologic, immunohistochemical, and molecular genetic study of 144
cases. Am J Surg Pathol 2001; 25: 1121-1133
182. Ranchod M.,
Kempson R.L.: Smooth Muscle Tumors of the Gastrointestinal Tract and
Retroperitoneum: a pathologic analysis of 100 cases. Cancer
1977; 39: 255-262
183. Evans H.L.:
Smooth Nuscle Tumors of the Gastrointestinal Tract. A study of 56 cases
followed for a minimum of 10 years. Cancer 1985; 56: 2242-2250
184. Franquemont
D.W.: Differentiation and Risk Assessment of Gastrointestinal Stromal Tumors. Am J Clin
Pathol 1995; 103: 41-47
185. De Saint
Aubain Somerhausen N., Fletcher C.D.M.: Gastrointestinal Stromal Tumors: An
update. Sarcoma 1998; 2: 133-141
186. Singer S.,
Rubin B.P., Lux M.L., et al.: Prognostic Value of KIT Mutation Type, Mitotic
Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors. J Clin
Oncol 2002; 20: 3898-3905
187. Νg Ε.Η., Pollock
R.E., Munsell M.F., et al.: Prognostic Factors Influencing Survival in Gastrointestinal
Leiomyosarcomas: implications for surgical management and staging. Ann Surg
1992; 215: 68-77
188. Ernst S.I.,
Hubbs A.E., Przygodzki R.M. et al.: KIT Mutation Portends Poor Prognosis in
Gastrointestinal Stromal/Smooth Muscle Tumors. Lab Invest 1998; 78:
1633-1636
189. Lasota J.,
Jasinski M., Sarlomo-Ricala M., et al.: Mutations in Exon 11 of c-kit Occur
Preferentially in Malignant Versus Benign Gastrointestinal Stromal Tumors and
dont Occur in Leiomyomas or Leiomyosarcomas. Am J Pathol 1999; 154: 53-60
190. Taniguchi M., Nishida T., Hirota S.
et al: Effect of the c-kit Mutation on Prognosis of Gastrointestinal Stromal
Tumors. Cancer Res 1999; 59: 4297-4300
191. Rudolph P.,
Gloeckner K., Parwaresch R., et al.: Immunophenotype, DNA ploidy, and
Biological Behavior of Gastrointestinal Stromal Tumors: a multivariate
clinicopathologic study. Hum Pathol 1998; 29: 791-800
192. Panizo-Santos
A., Sola I., Vega F., et al.: Predicting Metastatic Risk of Gastrointestinal
Stromal Tumors: role of the cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol 2000; 8: 133-144
193. Al-Bozom
I.A.: p53 Expression in gastrointestinal Stromal Tumors. Pathol Int
2001; 51: 519-523
194. Cunnigham
R.E., Abbondanzo S.L., Chu W.S., et al.: Apoptosi, Bcl-2 Expression, and p53
Expression in Gastrointestinal Stromal/Smooth Muscle Tumors. Appl
Immunohistochem Mol Morphol 2001; 9: 19-23
195. Schneider-Stock
R., Boltze C., Lasota J., et al.: High Prognostic Value of p16INK4 Alterations
in Gastrointestinal Stromal Tumors. J Clin Oncol 2003; 21: 1688-1697
196. Takahashi
R., Tanaka S., Kitadai Y., et al.: Expression of vascular Endothelial Growth
Factor and Angiogenesis in Gastrointestinal Stromal Tumors of the Stomach. Oncology
2003; 64: 266-274
197. Amin M.B.,
Ma C.K., Linden M.D., et al.: Prognostic Value of Proliferating Cell Nuclear
Antigen Index in Gastric Stromal Tumors. Correlation with Mitotic Count and
Clinical Course. Am J Clin Pathol 1993; 100: 428-432
198. Kiyabu
M.T., Bishop P.C., Parker J.W., et al.: Smooth Muscle Tumors of the
Gastrointestinal Tract.Flow Cytometric Quantitation of DNA and Nuclear Antigent
Content and Correlation with Histologic Grade. Am J Surg Pathol 1988; 12:
954-960.
199. Cooper
P.N., Quirke P., Hardy G.J., et al.: A Flow Cytometric, Clinical and
Histological Study of Stromal Neoplasms of the Gastrointestinal Tract. Am J Surg
Pathol 1992; 16: 163-170
200. Pauser U.,
Schmedt auf der Günne N., Klöppel N., et al.: p53 Expression is Significantly
Correlated wit High Risk of Malignancy and Epithelioid Differentiation in
GISTs. An immunohistochemical analysis of 104 cases. BMC Cancer
2008; 8: 204
201. Sakurai S.,
Fukayama M., Kaizaki Y et al.: Telomerase activity in Gastrointestinal Stromal
Tumors. Cancer 1998; 83: 2060-2066
202. Günther T.,
Schneider-Stock R., Häckel C., et al.: Telomerase Activity and Expression of
hTR in Gastrointestinal Stromal Tumors in Comparison with Extragastrointestinal
Sarcomas. Clin Cancer Res 2000; 6:
1811-1818
203. Kawai J.,
Kodera Y., Fujiwara M., et al.: Telomerase Activity as Prognostic Factor in
Gastrointestinal Stromal Tumors of the Stomach. Hepatogastroenterology 2005;
52: 959-964
204. DeMatteo
R.P., Shah A., Fong Y., et al.: Results of Hepatic Resection for Sarcoma
Metastatic to Liver. Ann Surg 2001; 234: 540-547, discussion 547-548
205. Gottlieb
J.A., Baker L.H., O’Bryan R.M., et al.: Adriamycin (NSC123127) Used Alone and
in Combination for Soft Tissue and Bony Sarcomas. Cancer Chemother Rep Part 3.
1975; 6: 271-282
206. Trent J.C.,
Beach J., Burgess M.A., et al.: A Two-arm Phase II Study of Temozolomide in
Patients with Advanced Gastrointestinal Stromal Tumors and Other Soft Tissue
Sarcomas. Cancer 2003; 98: 2693-2699
207. Edmonson
J.H., Ryan L.M., Blum R.H., et al.: Randomized Comparison of Doxorubicin Alone
Versus Ifosfamide plus Doxorubicin or Mitomycin, Doxorubicin, and Cisplatin
Against Advanced Soft Tissue Sarcomas. J Clin Oncol 1993; 11: 1269-1275
208. Plaat B.E.,
Hollema H., Molenaar W.M., et al.: Soft
Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors:
Differences in clinicak outcome and expression of multidrug resistance proteins.
J Clin Oncol 2000; 18: 3211-3220
209. Bilimoria
M.M., Holtz D.J., Mirza N.Q. et al.: Tumor Volume as a Prognostic Factor for
Sarcomatosis. Cancer 2002; 94: 2441-2446
210. Eilber
F.C., Rosen G., Forchr C. et al.: Surgical Resection and Intraperitoneal
Chemotherapy for Recurrent Abdominal Sarcomas. Ann Surg Oncol 1999; 6: 645-650
211. Mavligit
G.M., Zukwiski A.A., Ellis L.M., et al.: Gastrointestinal Leiomyosarcoma
Metastatic to the Liver. Durable Tumor Regression by Hepatic Chemoembolization
Infusion with Cisplatin and Vinblastine. Cancer 1995; 75: 2083-2088
212. Mallucio
M.A., Covey A. M., Schubert J. et al.: Treatment of Metastatic Sarcoma of the
Liver with Bland Embolization. Cancer 2006; 107: 1617-1623
213. Katz S.C.,
DeMatteo R.P.: Gastrointestinal Stromal Tumors and Leiomyosarcomas. J Surg
Oncol 2008; 97: 350-359
214.Van
Oosterom A.T., Judson I., Verweij J., et al.: Safety and Efficacy of Imatinib
(STI571) in Metastatic Gastrointestinal Stromal Tumours: A phase I study. Lancet
2001; 358: 1421-1423
215. Demetri
G.D., von Mehren M., Blanke C.D., et al.: Efficacy and Safety of Imatinib
Mesylate in Advanced Gastrointestinal Stromal Tumors. N Engl J
Med 2002; 347: 472-480
216. Verweij J.,
Casali P.G., Zalcberg J., et al.: Progression-free Survival in Gastrointestinal
Stromal Tumors with High-dose Imatinib: Randomised trial. Lancet
2004; 364: 1127-1134
217. DeMatteo
R., Maki R.G., Singer S., et al.: Results of Tyrosine Kinase Inhibitor Therapy
followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Ann Surg
2007; 245: 347-352
218. Van
Glabbeke M., Verweij J., Casali P.G., et al.: Initial and Late Resistance to
Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different
Prognostic Factors: A European Organization for Research and Treatment of
Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study. J Clin
Oncol 2005; 23: 5795-5804
219. Antonescu
C.R., Besmer P., Guo T., et al.: Aquired Resistance to Imatinib in
Gastrointestinal Stromal Tumors Occurs Through Secondary Gene Mutation. Clin Cancer
Res 2005; 11: 4182-4190
220. Debiek-Rychter
M., Cools J., Dumez H., et al.: Mechanisms of Resistance to Imanitib Mesylate
in Gastrointestinal Stromal Tumors and Activity of the PKC412 Inhibitor Against
Imatinib-Resistant Mutants. Gastroenterology 2005; 128: 270-279
221. Prenen H.,
Cools J., Mentens N., et al.: Efficacy of the Kinase Inhibitor SU11248 Against
Gastrointestinal Stromal Tumors Mutants Refractory to Imatinib Mesylate. Clin Cancer
Res 2006; 12: 2622-2627
222. Demetri G.,
Desai J., Fletcher J. et al.: SU11248. A Multitargeted Tyrosine Kinase
Inhibitor, Can Overcome Imatinib (IM) Resistance Caused by Diverse Genomic
Mechanisms in Patients with Metastatic Gastrointestinal Stromal Tumor (GIST). J
Clin Oncol 2004, ASCO Annual Meeting Proceedings (post meeting edition); 22,No
14S (July 15 Supplement), 3001
223. DeMatteo
R.: Adjuvant Imatinib Mesylate in Patients with Primary High Risk
Gastrointestinal Stromal Tumor (GIST) Following Complete Resection: Safety
Results from the U.S. Intergroup Phase
II Trial ACOSOG Z9000. In ASCO 2005
224. Blackstein
M.E., Blay J.Y., Corless C., et al.: Gastrointestinal Stromal Tumours:
Consensus statement on diagnosis and treatment. Can J Gastroenterol 2006;
20: 157-163
225. Choi H.,
Chamsangavej C., de Castro Faria S., et al.: CT Evaluation of the Response of
Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A
quantititative analysis correlated with FDG PET findings. AJR Am J
Roentgenol 2004; 183: 1619-1628
226. Stroszczynski
C., Jost J., Reichardt P., et al.: Follow-up of Gastrointestinal Stromal Tumors
(GIST) During Treatment with Imatinib Mesylate by Abdominal MRI. Eur Radiol
2005; 15: 2448-2456
227. Le Cesne
A., Perol D., Ray-Coquard I., et al.: Interruption of Imanitib (IM) in GIST
Patients with Advanced Disease: Updated results of the prospective French
Sarcoma Group randomized phase III trial on survival and quality of live
(abstract 9031). J Clin Oncol 2005, ASCO Annual Meeting Proceeding; 23, No 16S,
Part-I of II (June 1 supplement),9031
228. Casali P.G., Jost L., Reichardt P., et al.:
Gastrointestinal Stromal Tumors: ESMO clinical recommendations for diagnosis,
treatment and folow up. Ann Oncol 2009; 20 (suppl.4): 64-67
229. National
Comprehensive Cancer Network. The NCCN Soft Tissue Sarcoma Clinical Practice
Guidlines in Oncology (Version 1.2009I). National Comprehensive Cancer
Network, PA, USA ,2009
230. Debiek-Rychter
M., Sciot R., Le Cesne A., et al.: KIT Mutations and Dose Selection for
Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors. Eur J
Cancer 2006; 42: 1093-1103
231. Blay J. Y.,
Le Cesne A., Ray-Coquard I et al.: Prospective Multicentric Randomized Phase
III Study of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors
Comparing Interruption Versus Continuation of Treatment Beyon 1 Year: the
French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113
232. Benjamin
R.S., Choi H., Macapinlac H.A., et al.: We Should Desist Using RECIST, at Least
in GIST. J Clin Oncol 2007; 25: 1760-1764
233. Blanke
C.D., Demetri G.D., von Mehren M., et al.: Long-term Results from a Randomized
Phase II Trial of Standard-Versus Higher-dose Imatinib Mesylate for Patients
with Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT.
J Clin Oncol 2008; 26: 620-625
234. Hasan I.,
You Y. N., Shyyan R., et al.: Surgically Managed Gastrointestinal Stromal
Tumors: a comparative and prognostic analysis. Ann Surg Oncol 2008; 15:
52-59
235. Blanke
C.D., Rankin C., Demetri G.D., et al.: Phase III Randomized, Intergroup Trial
Assessing Imatinib Mesylate at Two Dose Levels in Patients with Unresectable or
Metastatic Gastrointestinal Tumors Expressing the KIT Receptor Tyrosine Kinase:
S0033. J Clin Oncol 2008; 26: 626-632
236. Chen H.,
Pruit A., Nicol T., et al.: Complete Hepatic Resection of Metastases from
Leiomyosarcoma Prolongs Survival. J Gastrointest Surg 1998; 2: 151-155
237. Bauer S.,
Hartmann J.T., de Witt M., et al.: Resection of Residual Disease in Patients with Metastatic Gastrointestinal
Stromal Tumors Responding to Treatment with Imatinib. Int J
Cancer 2005; 117: 316-325
238. Bonvalot
S., Eldweny H., Pechoux C.L., et al.: Impact of Surgery on Advanced
Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era. Ann Surg
Oncol 2006; 13: 1596-1603
239. Rutkowski
P., Nowecki Z., Nyckowski P., et al.: Surgical Treatment of Patients with
Initially Inoperable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)
During Therapy with Imatinib Mesylate. J Surg Oncol 2006; 93: 304-311
240. Hasegawa
J., Kanda T., Hirota S., et al.: Surgical Interventions for Focal Progression
of Advanced Gastrointestinal Stromal Tumors During Imatinib Therapy. Int J Clin
Oncol 2007; 12: 212-217
241. Gronchi A.,
Fiore M., Miseli F., et al.: Surgery of Residual Disease Following
Molecular-Targeted Therapy with Imatinib Mesylate in Advanced/Metastatic Gist. Ann Surg
2007; 245: 341-346
242. Sym S. J.,
Ryu M.H., Lee J.L., et al.: Surgical Intervention Following Imatinib Treatment
in Patients with Advanced Gastrointestinal Stromal Tumors (GISTs). J Surg
Oncol 2008; 98: 27-33
243. Adenis A.,
Cassier P., Bui B.N., et al.: Does Interruption of Imatinib (IM) in Responding
Patients After Tree Years of Treatment Inflyence of Outcome of Patients with
Advanced GIST Included in the BFR14 Trial? J Clin Oncol 2008; 28(Suppl.),
(abstr. 10522)
244. Raut C.P.,
Posner M., Desai J., et al.: Surgical Management of Advanced Gastrointestinal
Stromal Tumors After Treatment with Targeted Systemic Therapy Using Kinase
Inhibitors. J Clin Oncol 2006; 24: 2325-2331
245. Eisenberg
B.L., Judson I.: Surgery and Imanitib in the Management og GIST: emerging
approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11:
465-475
246. Radiation
Therapy Oncology Group, National Cancer Institute (NCI), American College of
Radiology Imaging Network, Eastern Cooperative Oncology Group. RTOG S-0132. A
Phase II trial of neoadjuvant/adjuvant STI-571 (Gleevec NSC#716051) for primary
and reccurent operable malignant GIST expressing the KIT receptor tyrosine
kinase (CD 11). (NCT identifier: NCT00028002) (2009)
247. Eisenberg
B.L., Harris J., Blanke C.D., et al.: Phase II Trial of Neoadjuvant/adjuvant
Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Reccurent Operable
Gastrointestinal Stromal Tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg
Oncol 2009; 99: 42-47
248. Mieetinen
M., Lasota J.: Gastrointestinal Stromal Tumors: pathology and prognosis at
different sites. Semin Diagn Pathol 2006; 23: 70-83
249. De Matteo
R.P., Gold J.S., Saran L., et al.: Tumor Mitotic Rate, Size, and Location
Indepedently Predict Recurrence After Resection of Primary Gastrointestinal
Stromal Tumor (GIST). Cancer 2008; 112: 608-615
250. De Matteo
R.P., Owzar K., Antonescu C.R., et al.: Efficacy of Adjuvant Imatinib Mesylate
Following Complete Resection of Localized Primary Gastrointestinal Stromal
Tumor (GIST) at High Risk of Recurrence. The U.S. Intergroup Phase II Trial
ACOSOG Z9000. Gastrointest. Cancers Sympos. Orlando,FL,USA, Jan. 2008, (abstr. 8)
251. De Matteo
R.P., Owzar K., Maki R., et al.: Adjuvant Imatinib Mesylate Increases
Recurrence Free Survival (RFS) in Patients with Completed Resected Localized
Primary Gastrointestinal Tumor (GIST): North American Inergroup Phase III Trial
ACOSOG Z9001. ASCO Annual Meeting. Chicago,IL,USA, Jun 2007 (abstr. 10079)
252. De Matteo
R.P., Ballman K. V., Antonescu C.R., et al.: Adjuvant Imatinib Mesylate After
Resection of Localised , Primary Gastrointestinal Stromal Tumor: a randomised
Double-blind, Placebo-controlled Trial. Lancet 2009; 373: 1097-1104
253. Shen L., Li
J., Li J., et al.: Adjuvant Post-Surgery Therapy with Imatinib in Intermediate
or High-Risk Gastrointestinal Stromal Tumour (GIST) Patients: Interim Analysis
from a Single Centre Comparison Study. Ann Oncol 2008; 19(suppl. 8),Viii
267 (abstr. 870 PD)
254. Kang Y.,
Kang B.W., Ryu M., et al.: A Phase II Study of Imatinib Mesylate as Adjuvant
Treatment for Curatively Resected High-Risk Localized Gastrointestinal Stromal Tumors
with c-KIT exon 11 Mutation.
Gastrointest. Cancers Sympos. Science and Multidisciplinary Management of GI
Malignancies. Jan. 2009, San Frasisco, CA,USA, (abstr. 95)
255. European
Organization for Research and Treatment of Cancer, Italian Sarcoma Group, Federation
Nationale des Centres de Lutte Centre le Cancer, Sarcomas Gedle. EORTC 62024.
Intermediate and High Risk Localized, Completly Resected, Gastrointestinal
Stromal Tumors (GIST) Expressing KIT Receptor: a controlled randomized trial on
adjuvant imatinib mesylate (Glivec) versus no further therapy after complete
surgery. (NTC identifier: NCT00103168) (2009)
256. Scandinavian
Sarcoma Group. SSGXVIII/AIO. Short (12 months) Versus Long (36 months) Duration
of Adjuvant Treatment with the Tyrosine Kinase Inhibitor Imatinib Mesylate of
Operable GIST with a High Risk of Recurrence. (NCT identifier:
NCT00116935) (2009)
Disclaimer:
H παρούσα μελέτη ουδεμίας χορηγίας ή επιχορηγήσεως έτυχε. Οι
παρεχόμενες εδώ πληροφορίες δεν θα πρέπει να υποκαταστήσουν την παροχή συμβουλών
από εξειδικευμένους πάροχους υγείας. Τουναντίον, οι πληροφορίες αυτές έχουν
εκπαιδευτικό χαρακτήρα και ενημερωτικό σκοπό αποτεινόμενο προς συναδέλφους
ιατρούς. Κατ’ ουδένα τρόπο πρέπει να θεωρούνται ιατρικές συμβουλές παρεχόμενες
προς ασθενείς. Παρακαλείσθε όπως αναζητήσετε κατάλληλη ιατρική συμβουλή, εάν
έχετε υποψίες ότι πάσχετε από ανάλογες παθήσεις.
Επιστροφή στο ευρετήριο
Επιστροφή στο ευρετήριο
